- Home
- LSBK vs CRDL Comparison
LSBK vs CRDL Comparison
Compare LSBK & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- CRDL
- Stock Information
- Founded
- LSBK 1891
- CRDL 2017
- Country
- LSBK United States
- CRDL Canada
- Employees
- LSBK N/A
- CRDL N/A
- Industry
- LSBK Savings Institutions
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSBK Finance
- CRDL Health Care
- Exchange
- LSBK Nasdaq
- CRDL Nasdaq
- Market Cap
- LSBK 90.0M
- CRDL 90.4M
- IPO Year
- LSBK 2006
- CRDL N/A
- Fundamental
- Price
- LSBK $13.01
- CRDL $1.06
- Analyst Decision
- LSBK
- CRDL Strong Buy
- Analyst Count
- LSBK 0
- CRDL 2
- Target Price
- LSBK N/A
- CRDL $9.00
- AVG Volume (30 Days)
- LSBK 21.9K
- CRDL 781.9K
- Earning Date
- LSBK 10-22-2025
- CRDL 11-13-2025
- Dividend Yield
- LSBK 2.77%
- CRDL N/A
- EPS Growth
- LSBK 39.59
- CRDL N/A
- EPS
- LSBK 1.05
- CRDL N/A
- Revenue
- LSBK $26,488,000.00
- CRDL N/A
- Revenue This Year
- LSBK N/A
- CRDL N/A
- Revenue Next Year
- LSBK N/A
- CRDL N/A
- P/E Ratio
- LSBK $12.38
- CRDL N/A
- Revenue Growth
- LSBK 1.75
- CRDL N/A
- 52 Week Low
- LSBK $11.50
- CRDL $0.77
- 52 Week High
- LSBK $13.48
- CRDL $2.24
- Technical
- Relative Strength Index (RSI)
- LSBK 47.09
- CRDL 41.54
- Support Level
- LSBK $12.88
- CRDL $1.04
- Resistance Level
- LSBK $13.09
- CRDL $1.16
- Average True Range (ATR)
- LSBK 0.14
- CRDL 0.06
- MACD
- LSBK -0.00
- CRDL 0.00
- Stochastic Oscillator
- LSBK 26.00
- CRDL 0.00
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.